About: Repurposing of Kinase Inhibitors for Treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Repurposing of Kinase Inhibitors for Treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Repurposing of Kinase Inhibitors for Treatment of COVID-19
Creator	Meng, Chengcheng Sattler, Martin Buhrlage, Sara Weisberg, Ellen Yang, Priscilla Gray, Nathanael Griffin, James Liu, Qingsong Liu, Qingwang Parent, Alexander Wang, Jinhua
source	Medline; PMC
abstract	The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community. In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening. There are numerous protein kinases associated with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity. Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1007/s11095-020-02851-7
bibo:pmid	32778962
has license	no-cc
sha1sum (hex)	9d37f86567a543cc9b896e41a9703967f0dc2085
schema:url	https://doi.org/10.1007/s11095-020-02851-7
resource representing a document's title	Repurposing of Kinase Inhibitors for Treatment of COVID-19
has PubMed Central identifier	PMC7417114
has PubMed identifier	32778962
schema:publication	Pharm Res
resource representing a document's body	covid:9d37f86567a543cc9b896e41a9703967f0dc2085#body_text
is schema:about of	named entity 'ALLOW' named entity 'THEIR' named entity 'OUTBREAK' named entity 'VACCINE' named entity 'TREATMENTS' named entity 'CLINICAL TRIALS' named entity 'ANTI-INFLAMMATORY ACTIVITY' named entity 'SCIENTIFIC' named entity 'infection' named entity 'SARS-CoV-2' named entity 'approved drugs' named entity 'antiviral agents' named entity 'immunosuppression' named entity 'sorafenib' named entity 'volume of distribution' named entity 'boxed warning' named entity 'antiinflammatory' named entity 'kinase inhibitors' named entity 'nilotinib' named entity 'antifibrotic' named entity 'tofacitinib' named entity 'FDA' named entity 'protease inhibitors' named entity 'EGFR' named entity 'AML' named entity 'plasma protein bound' named entity 'GAK' named entity 'Osimertinib' named entity 'virus' named entity 'afatinib' named entity 'IL-6' named entity 'tuberculosis' named entity 'cell signaling' named entity 'cell entry' named entity 'ritonavir' named entity 'ritonavir' named entity 'sterilizing' named entity 'protein targets' named entity 'infection' named entity 'interstitial lung disease' named entity 'antibody' named entity 'siRNA' named entity 'influenza' named entity 'receptor' named entity 'nintedanib' named entity 'dasatinib' named entity 'SARS-CoV' named entity 'oncogene' named entity 'approved drugs' named entity 'inhibitory activity' named entity 'drug therapies' named entity 'antiviral activity' named entity 'antiviral' named entity 'MERS' named entity 'bioavailability' named entity 'caveolin' named entity 'ARDS' named entity 'immunotoxicity' named entity 'toxicity' named entity 'antiviral agents' named entity 'vesicles' named entity 'coronavirus' named entity 'SRC kinase' named entity 'infection' named entity 'viruses' named entity 'fungal infection' named entity 'plasma levels' named entity 'cytokines' named entity 'infection' named entity 'SARS-CoV-2' named entity 'influenza virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software